Evidence map›Paper›PMID 41290870›Full record

ArticleScientific reports2025

Increase of intracellular Zn

Yoko Yoshikawa, Motohiko Naito, Aki Emi, Kei Okada, Naoto Fujishima, Hironori Edamatsu, Shigeyuki Matsumoto, Haruka Taniguchi, Tohru Kataoka

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yoko YoshikawaDivision of Molecular Biology, Department of Biochemistry and Molecular Biology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650 - 0017, Japan. yokoyosh@topaz.kobe-u.ac.jp.
Motohiko NaitoDivison of Molecular and Pharmaceutical Sciences, Department of Physiology and Cell Biology,, Kobe University Graduate School of Medicine, Kobe University Incubation Center Rm, 404, 1-5-6 Minatojima-Minami-machi, Chuo-ku, Kobe, 650 - 0047, Japan.
Aki EmiDivision of Molecular Biology, Department of Biochemistry and Molecular Biology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650 - 0017, Japan.
Kei OkadaDivison of Molecular and Pharmaceutical Sciences, Department of Physiology and Cell Biology,, Kobe University Graduate School of Medicine, Kobe University Incubation Center Rm, 404, 1-5-6 Minatojima-Minami-machi, Chuo-ku, Kobe, 650 - 0047, Japan.
Naoto FujishimaDivision of Molecular Biology, Department of Biochemistry and Molecular Biology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650 - 0017, Japan.
Hironori EdamatsuDivision of Molecular Biology, Department of Biochemistry and Molecular Biology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650 - 0017, Japan.
Shigeyuki MatsumotoDivision of Molecular Biology, Department of Biochemistry and Molecular Biology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650 - 0017, Japan.
Haruka TaniguchiDivision of Molecular Biology, Department of Biochemistry and Molecular Biology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650 - 0017, Japan.
Tohru KataokaDivision of Molecular Biology, Department of Biochemistry and Molecular Biology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650 - 0017, Japan. kataoka@people.kobe-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phospholipase Cε (PLCε) has been shown to augment inflammation and inflammation-associated carcinogenesis by inducing proinflammatory cytokine expression through activation of nuclear factor-κB (NF-κB), making it a candidate molecular target for development of anti-inflammatory and cancer-preventive agents. Aiming at developing its selective inhibitor, we carry out a high-throughput screening of 68,114 compounds by using a fluorogenic substrate and discover zinc pyrithione (ZPT) as an ε class-specific PLC inhibitor whose IC

Indexed as

InflammationPhosphoinositide Phospholipase CZincAnimalsCell Line, TumorColitisHumansMiceNF-kappa BOrganometallic CompoundsProtein Kinase CPyridinesThionesNF-kappa BOrganometallic CompoundsPhosphoinositide Phospholipase Cphospholipase C epsilonProtein Kinase CPyridinespyrithione zincThionesZincAnti-inflammationCancer preventionPLCεZinc pyrithioneZn2+Ε class-specific PLC inhibitor

Identifiers

PMID41290870
PMCPMC12647759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.